entertainment -WSS

entertainment

author：leisure time 2025-08-12 06:42:46 - browse：3

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Blood tests recalled over risk of missed heart attack diagnosis

WSS

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Structure Therapeutics oral GLP

Eli Lilly to acquire Versanis in heated race for weight loss drugs

The most pressing bird flu mysteries scientists want answered

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

BD to buy Edwards patient monitoring unit for $4.2 billion

entertainment

entertainment

Wikipedia

Heart attack and stroke risk calculators need revising

The most pressing bird flu mysteries scientists want answered

Duchenne breakthrough therapy leaves behind pioneering families

Congress likely to miss an opportunity to fix drug shortages issue

Apple is now the first public company to be valued at $3 trillion

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Peter Hotez and the public health issue of online harassment

Involuntary treatment for addiction doesn't work

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Mike Pence clashes with Tucker Carlson in Iowa

Wikipedia

Argenx drug significantly slows progression of nerve disorder

Federal judge rules Oregon’s tough new gun law is constitutional

Argenx drug significantly slows progression of nerve disorder

CMS got Medicare Advantage quality rating wrong, judge rules

Sutter Health’s antitrust win overturned by appeals court

Elevance PBM president out as customers face prescription chaos

Wikipedia

hotspot

explore

Wikipedia